As the healthcare demand stabilizes in the post-pandemic era, the European market is experiencing corporate mergers and adjustments in response to MDR regulatory requirements, alongside trade challenges stemming from geopolitical factors. In 2024, the global respiratory medical device market stands at a crucial turning point. With a focus on professional interface technology in respiratory therapy, GaleMed has completed the stringent MDR certification process. As we navigate the new market landscape and technological expectations, we are pleased to announce that Mr. Thomas Willemsen has joined GaleMed Corporation as our new Chief Executive Officer.

Mr. Willemsen brings over 25 years of executive leadership experience in the pharmaceutical industry, having held positions such as General Manager of Merck KGaA in Taiwan, General Manager of GSK in Taiwan, General Manager and Chairman of GSK China, Senior Vice President Asia Pacific for Takeda, and CEO of Tessa Therapeutics, a biotech startup in Singapore. His extensive international business experience and leadership skills will propel GaleMed into a new era.

"I am excited to join the GaleMed family and collaborate with our experienced and professional team to drive business expansion. Through strategic initiatives, we will continue to grow our presence in the global respiratory medical technology and anesthesia markets. Together, let’s build a stronger and more distinguished GaleMed." Willemsen stated.

Looking ahead, with Willemsen’s insights and leadership in international markets, GaleMed aims not only to respond passively to market trends but also to actively shape the future of respiratory care. We remain committed to fostering innovation, ensuring regulatory compliance, and practicing sustainability to create greater value for patients, healthcare providers, and business partners, while achieving excellence in the global respiratory medical device market.